PHOENIX trial

From Ganfyd

Jump to: navigation, search
Name of Trial: PHOENIX trial
Full Name
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Type of Trial
RCT.
Studied
Comparing R-CHOP and R-CHOP with ibrutinib for newly diagnosed non-GC diffuse large B-cell lymphoma
Primary Outcome
Event-free survival
Other Outcomes
Progression-free survival, overall survival, complete response rate, time to worsening symptoms, various pharmacokinetic parameters of ibrutinib, number of participants affected by an adverse event
Summary
Still recruiting
Criticisms and Limitations
Clinical Trial Websites
Relevant Clinical Literature

On-going. See: https://clinicaltrials.gov/ct2/show/NCT01855750?term=DBL3001&rank=1

References

Personal tools